{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:05:44Z","timestamp":1747181144773,"version":"3.40.5"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,10]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Very-high-risk prostate cancer (PCa) is associated with poor prognosis. Radical prostatectomy (RP) is an option for selected high-risk PCa cases, especially in younger, healthier patients. However, a high Gleason score and high T stage can increase the risk of RP. Neoadjuvant therapy has been reported in high- or very-high-risk PCa, but its clinical use remains controversial.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses and patient concerns:<\/jats:title>\n            <jats:p>A 53-year-old male patient diagnosed with PCa was referred to our hospital. The patient\u2019s Gleason score was 4\u2009+\u20095, and the clinical stage was T4N0M0, with an abnormally enlarged prostate adhering to the rectum and leading to decreased mobility of the rectum, suggesting a very-high-risk PCa inappropriate for RP. However, instead of external beam radiation therapy, which is the standard treatment for inoperable PCa, the patient insisted on RP.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Androgen deprivation therapy plus docetaxel was chosen as the first downstaging treatment; however, the tumor was too slightly downsized to undergo RP. Therefore, zimberelimab was added after confirmation of a genomic feature of high microsatellite instability and high tumor mutational burden status.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After 4 doses of zimberelimab, the prostate shrank significantly. The patient successfully completed RP after another dose of zimberelimab, and achieved a pathological complete response (pCR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Our case represents a successful attempt at personalized treatment and provides preliminary evidence for the clinical use of downstaging therapy of androgen deprivation therapy, chemotherapy, and add-on zimberelimab for very-high-risk clinically localized PCa.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032870","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T16:02:26Z","timestamp":1676044946000},"page":"e32870","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Personalized downstaging treatment with ADT, chemotherapy and add-on zimberelimab for very-high-risk clinically localized prostate cancer: A case report"],"prefix":"10.1097","volume":"102","author":[{"given":"Jie","family":"Li","sequence":"first","affiliation":[{"name":"Department of Urology, Lishui Central Hospital and Fifth Affiliated Hospital of Wenzhou Medical College, Lishui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tengfei","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Urology, Lishui Central Hospital and Fifth Affiliated Hospital of Wenzhou Medical College, Lishui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengping","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Urology, Lishui Central Hospital and Fifth Affiliated Hospital of Wenzhou Medical College, Lishui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1490-7290","authenticated-orcid":false,"given":"Liang","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Guangzhou Gloria Biosciences Co. Ltd., Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8755-736X","authenticated-orcid":false,"given":"Ting","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Lishui Central Hospital and Fifth Affiliated Hospital of Wenzhou Medical College, Lishui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.eururo.2011.05.047","article-title":"Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.","volume":"60","author":"Akre","year":"2011","journal-title":"Eur Urol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2012.08.001","article-title":"Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.","volume":"63","author":"Rider","year":"2013","journal-title":"Eur Urol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2174\/1389450121666200621194409","article-title":"Neoadjuvant strategies before radical prostatectomy for high risk prostate cancer in the era of new hormonal agents.","volume":"22","author":"Tafuri","year":"2021","journal-title":"Curr Drug Targets"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"777318","DOI":"10.3389\/fonc.2021.777318","article-title":"Platinum-based neoadjuvant chemotherapy before radical prostatectomy for locally advanced prostate cancer with homologous recombination deficiency: a case report.","volume":"11","author":"Zhuang","year":"2022","journal-title":"Front Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"102019","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: evolution of the treatment paradigm.","volume":"86","author":"Tsimberidou","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.fertnstert.2018.05.006","article-title":"Personalized medicine: motivation, challenges, and progress.","volume":"109","author":"Goetz","year":"2018","journal-title":"Fertil Steril"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"e001065","DOI":"10.1136\/jitc-2020-001065","article-title":"Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA.","volume":"8","author":"Barata","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1002\/cncr.21926","article-title":"Radical prostatectomy for clinical T4 prostate cancer.","volume":"106","author":"Johnstone","year":"2006","journal-title":"Cancer"},{"key":"R12-20250504","first-page":"63936393","article-title":"Do physicians\u2019 attitudes towards patient-centered communication promote physicians\u2019 intention and behavior of involving patients in medical decisions?","volume":"17","author":"Wang","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41585-021-00514-9","article-title":"Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer.","volume":"18","author":"Devos","year":"2021","journal-title":"Nat Rev Urol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/PAP.0000000000000347","article-title":"Neoadjuvant hormonal therapy for prostate cancer: morphologic features and predictive parameters of therapy response.","volume":"29","author":"Wang","year":"2022","journal-title":"Adv Anat Pathol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and leukemia group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer.","volume":"38","author":"Eastham","year":"2020","journal-title":"J Clin Oncol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study.","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:02:24Z","timestamp":1746327744000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032870","relation":{},"ISSN":["0025-7974"],"issn-type":[{"type":"print","value":"0025-7974"}],"subject":[],"published":{"date-parts":[[2023,2,10]]}}}